H. Pylori Management

First-Line Treatment Recommendation

The American College of Gastroenterology recommends bismuth quadruple therapy for 14 days as the preferred first-line treatment for H. pylori infection, consisting of a PPI twice daily, bismuth subsalicylate or subcitrate, metronidazole, and tetracycline, with eradication rates of 80-90% even against metronidazole-resistant strains 1, 2
Bismuth quadruple therapy is preferred due to clarithromycin resistance now exceeding 15% in most regions of North America and Europe, making traditional triple therapy unacceptably ineffective 1, 2

The American Gastroenterological Association recommends a bismuth quadruple therapy regimen for 14 days, including PPI twice daily, bismuth subsalicylate 262 mg four times daily or bismuth subcitrate 120 mg four times daily, metronidazole 500 mg three to four times daily, and tetracycline 500 mg four times daily 1

The European Helicobacter Study Group recommends concomitant non-bismuth quadruple therapy for 14 days as an alternative first-line option when bismuth is unavailable, consisting of a PPI twice daily, amoxicillin, clarithromycin, and metronidazole 1, 2
The American College of Gastroenterology recommends triple therapy for 14 days as an alternative first-line option in regions with low clarithromycin resistance (<15%), consisting of a PPI twice daily, clarithromycin, and amoxicillin 3, 2

The American Gastroenterological Association recommends bismuth quadruple therapy for 14 days as second-line treatment if it was not used first-line, and levofloxacin triple therapy for 14 days if bismuth quadruple therapy has already been used 1, 2

The European Helicobacter Study Group recommends always prescribing 14 days of treatment to improve eradication success by approximately 5% compared to 7-10 day regimens 3, 4, 1, 2
The American College of Gastroenterology recommends high-dose PPI twice daily, with esomeprazole or rabeprazole 40 mg twice daily increasing cure rates by 8-12% compared to other PPIs 1, 2

The American Gastroenterological Association recommends testing for eradication success at least 4 weeks after completing therapy using urea breath test or validated monoclonal stool antigen test 1, 2

The European Helicobacter Study Group strongly recommends H. pylori eradication for active or history of peptic ulcer disease, gastric MALT lymphoma, first-degree relatives of patients with gastric cancer, and previous gastric neoplasia treated by endoscopic or subtotal gastric resection 3, 2

The American College of Gastroenterology notes that smoking increases eradication failure risk (odds ratio 1.95) and high BMI increases failure risk due to lower drug concentrations at the gastric mucosal level 1

The American Gastroenterological Association recommends considering probiotics to reduce antibiotic-associated diarrhea and improve compliance, but notes that probiotics have no solid evidence to increase eradication rates 1